Acarbose
Acarbose is an alpha-glucosidase inhibitor used to reduce postprandial glucose excursions. It acts mainly in the small intestine, where it slows the breakdown of complex carbohydrates into absorbable monosaccharides. It also partially inhibits pancreatic alpha-amylase. Because very little unchanged acarbose is absorbed systemically, most of its pharmacological action occurs inside the gastrointestinal tract.
Glucose and insulin. By delaying carbohydrate digestion, acarbose lowers the height and speed of post-meal glucose rises and usually reduces the accompanying insulin response. In type 2 diabetes, its average effect on HbA1c is modest, commonly around half to one percentage point depending on baseline control and background therapy. It is weight neutral for most patients and carries little intrinsic risk of hypoglycemia when used alone.
If hypoglycemia occurs because acarbose is combined with insulin or another glucose-lowering drug, treatment requires direct glucose rather than ordinary sucrose, because acarbose delays sucrose digestion.
Clinical use. Acarbose is used mainly in type 2 diabetes and in some settings of impaired glucose tolerance, especially when postprandial hyperglycemia is prominent. It is taken with the first bites of a carbohydrate-containing meal so that the drug and dietary carbohydrate are present in the intestine at the same time.
Gastrointestinal effects. Undigested carbohydrate reaches the colon, where bacteria ferment it. This produces the characteristic adverse effects: flatulence, bloating, abdominal discomfort and diarrhea. These symptoms are dose dependent and often improve after gradual titration or adaptation. They are also mechanistically linked to one of acarbose's most interesting geroscience effects: altered colonic fermentation.
Microbiota and short-chain fatty acids. By increasing the amount of carbohydrate reaching the large intestine, acarbose changes microbial substrate availability and can increase production of short-chain fatty acids such as acetate, propionate and butyrate. In animal studies, changes in microbiota composition and fermentation correlate with metabolic and survival effects. Whether a specific microbiome profile is necessary for benefit remains unresolved.
Animal longevity. Acarbose is one of the more reproducible pharmacologic lifespan interventions identified by the U.S. National Institute on Aging Interventions Testing Program. In genetically heterogeneous mice, chronic dietary acarbose produced a large increase in median lifespan in males, on the order of about 20% in key experiments, and a smaller effect in females. Later-start studies also showed benefit, particularly in males.
This sex difference is a major feature of the mouse data. Proposed explanations include differences in glucose handling, hormones, body composition and microbiota. The result demonstrates that blunting carbohydrate absorption can influence mammalian aging biology, but it does not establish that the same magnitude of effect occurs in humans.
Healthspan in mice. Treated older mice have shown improvements in selected age-related outcomes, including lower postprandial glucose excursions and reductions in some pathologies. Studies have reported sex-specific effects on tumors, kidney pathology, liver degeneration and motor performance. These data support a healthspan signal in addition to survival.
Human cardiovascular and diabetes-prevention research. Clinical studies in people with impaired glucose tolerance have reported reduced progression to diabetes and, in some analyses, favorable cardiovascular signals. Human data are substantially stronger for glycemic control than for longevity. No randomized trial has shown that acarbose extends human lifespan.
Why it interests geroscience. Acarbose reduces glucose and insulin peaks without requiring systemic drug exposure, modifies nutrient flow to the colon and changes microbial fermentation. These effects touch nutrient-sensing pathways, glycation, insulin signaling and gut-derived metabolites — all relevant to aging biology.
Overall, acarbose is an established metabolic drug with unusually strong animal longevity evidence. Its human value is proven for selected glycemic indications, while its role as a longevity intervention remains unproven and cannot be inferred directly from the mouse lifespan effect.